A detailed history of Carroll Investors, Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Carroll Investors, Inc holds 246,985 shares of RXRX stock, worth $2.01 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares
246,985
Previous 162,740 51.77%
Holding current value
$2.01 Million
Previous $1.07 Million 55.69%
% of portfolio
0.94%
Previous 0.7%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$5.7 - $8.27 $480,196 - $696,706
84,245 Added 51.77%
246,985 $1.67 Million
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $485,286 - $704,976
81,974 Added 101.5%
162,740 $1.07 Million
Q2 2024

Aug 13, 2024

BUY
$7.35 - $10.05 $492,207 - $673,018
66,967 Added 485.3%
80,766 $605,000
Q1 2024

May 15, 2024

BUY
$9.13 - $15.52 $125,984 - $214,160
13,799 New
13,799 $137,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.47B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Carroll Investors, Inc Portfolio

Follow Carroll Investors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carroll Investors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Carroll Investors, Inc with notifications on news.